Introduction
IgA deficiency, the most common primary immunodeficiency, is known to be a heterogeneous clinical disorder (1) . Genetic studies indicate that susceptibility genes located in the major histocompatibility complex class III region may predispose homozygous individuals to this pathology (2, 3) . Environmental factors may also play a role in the occurence of IgA deficiency, as several pathologies including viral infections have been found associated with IgA deficiency (1) . Although the basic immunologic defect that gives rise to IgA deficiency is unknown, a number of in vitro immunological alterations have been identified. In vitro cell culture studies have revealed that mechanistically IgA deficiency can be classified into three groups: (a) an arrest in the B cell differentiation pathway (4); (b) an increased in suppressor T lymphocyte function (5, 6) ; and (c) a decrease in helper T lymphocyte function (6, 7) . It has been proposed that B cells from IgA-D patients have undergone an isotype switch towards IgA since peripheral B cells from these patients bear surface IgA although they do not differentiate into IgA producing cells (8) . Recently we developed B cell culture conditions in which an anti-CD40 mAb is presented by a CD32-transfected fibroblast cell line (CD40 system). This system provides the signals for B cell activation and proliferation, thus allowing us to determine the capacity of cytokines to enhance B cell proliferation and induce Ig synthesis (9, 10) .
In this context, the addition of IL-IO enhances short term B cell proliferation and more strikingly induces B cells to differentiate into high Ig secreting plasma cells ( 11) . The addition of particles of Staphylococcus aureus Cowan (SAC)' to the CD40 system results in considerable secretion of Igs in the absence of isotype switch (CD4O/SAC system) (12) . Recently a CD40 ligand was identified on activated T cells and its gene subsequently cloned (13, 14) . Cells transfected with the gene for CD40 ligand induce B cell activation and proliferation similar to the CD40 system under study in our laboratory (14) . The present study is aimed at determining whether different forms of IgA deficiency (acquired and primary) might be related to intrinsic B cell defects or to regulatory T cell abnormalities. In particular, the effects of IL-10 on Ig production by PBMNC 
Methods
Patients. Selective acquired IgA deficiency was observed in four patients (BEAU, BIG, ORM, and REB) among a group of 335 adult renal transplant recipients. The clinical and immunologic parameters of these patients have been reported previously (15) . These patients had normal Ig serum levels during maintenance hemodialysis and before grafting (0.8-4 g/l). An abrupt decline in IgA serum levels occurred 6 wk after transplantation concurrently with a transient hepatitis. Hepatitis occurred in one chronic hepatitis B (Hbs) carrier patient and in three others with active cytomegalovirus (CMV) disease. Selective IgA deficiency persisted over succeeding years. Immunosuppressive therapy was conventional (anti-thymocyte globulin, azathioprine and low dose corticosteroids).
Two adult patients who had primary IgA deficiency were included in this study: RAF, dialyzed but not transplanted, and BAC who had In addition, seven children between 4 and 14 years of age (one female and six male), referred in the past two years to the department of Pediatrics for immunologic evaluation for recurrent infections had low serum IgA. Children who had recurrent upper respiratory tract infections were treated by antibiotics and immunostimulatory therapy. Two of the children had I.V.Ig therapy treatment after pneumonia (TON and JUS). All subjects were Caucasian.
Six additional unrelated Caucasian adults (three male and three female) served as controls. Table I shows the significant clinical data available for the two groups of IgA-D patients.
Reagents. The anti-CD40 monoclonal antibody mAb89 was produced in our laboratory (16) . The CD32/FCyRII transfected Ltk-cell line (CD32 L cells) was described earlier (17) . Cell phenotypes were determined using anti-CD3, -CD4, -CD8, -CD19, -CD56 (anti-NK cells), and -CD14 (anti-monocytes) FITC conjugated mAbs originating from Becton Dickinson (Mountain View, CA). Purified rhIL-2 (Amgen Biologicals, Thousand Oaks, CA) (3 X 106 U/ml) and rhIL-10 (Schering-Plough Research Institute Dardilly, France) (1 x 107 U/ml) were respectively used at 20 U/ml and 100 ng/ml.
Isolation of cells and culture conditions. Peripheral blood mononuclear cells (PBMNC) were isolated using a standard Ficoll (d = 1,077 g/ml) gradient method. Peripheral blood B cells were first enriched in the E-fraction and submitted to anti-CD2, anti-CD3, and anti-CD14 mAbs negative selection with magnetic beads coated with anti-mouse IgG (Dynabeads; Dynal, Oslo, Norway) as described previously (18 ( 19) . Cultures were carried out in modified Iscove's medium as detailed previously (19) .
Cytokine production. 106 PBMNC of patients and normal donors were incubated in 1 ml culture medium with PHA (1 qg/ml) and SAC and 20 U/ml of IL-2 for 48 h. Supernatants were harvested and IL-10 and IFNy contents were determined by specific ELISAs described in detail elsewhere (20, 21) .
Results
Phenotyping of PBMNC from IgA-D patients. As shown in Table II (Table Ill) .
IL-10 induces IgA synthesis by PBMNC from IgA-D patients. As IL-lO has earlier been found to induce CD40-activated naive B cells to produce small amounts of IgA (12), we explored whether it would induce B cells from patients with IgA-D to produce IgA. Thus, PBMNC from the 13 IgA-D patients were cultured in the CD40/SAC system and in the presence of IL-1O. As shown in Fig. 1 , PBMNC from IgA-D patients activated by anti-CD40 mAb and SAC secreted IgA when IL-10 was added to cultures. The levels of IgA obtained varied from one patient to another. The quantities of IgA produced by the PBMNC from acquired IgA-D patients (Fig. 1 A) ranged from 0.3 to 1.6 ,ig/ml of IgA. Even more strikingly, PBMNC from primary IgA-D patients (Fig. 1 B) secreted up to 7.9 Mg/ml IgA in response to IL-10. While the mean IgA levels obtained with IgA-D PBMNC in response to IL-10 (mean+SD = 3±2.6 p.g/ml IgA, n = 13 IgA-D patients) was lower than of controls ( Fig. 1 C) (mean±SD = 10.8+2. 4 ,ug/ml IgA, n = 6 controls), it is noteworthy that some IgA-D patients produced as much IgA as controls.
As can be seen in Fig. 2 , the effect of IL-lO was not restricted to IgA isotype. Addition of IL-1O also increased IgG (2-5-fold) and IgM (3-10-fold) productions by activated PBMNC from normal donors and IgA-D patients. Cells from primary IgA-D patients produced almost as much IgG and IgM as controls, while those from acquired IgA-D produced less 1g. This may be related to the lower B cell numbers in acquired IgA-D patients (Table H) . As shown in Fig. 3 , IL-10 increased IgA secretion by PBMNC of both IgA-D patients (ZAR and MAR) and controls in a dose-dependent fashion. Significant IgA syn- thesis could be detected with 10 ng/ml of IL-10 and maximum IgA synthesis was obtained with 100 ng/ml of IL-10. IL-JO directly acts on B cells from IgA-D patients. Whenever the sample size allowed it, to determine whether IL-10 directly acts on B lymphocytes, these were purified from blood mononuclear cells by FACS-sorting CD19 positive cells (95% purity). B cells were then cultured with or without IL-10 in the CD40/SAC system. As shown in Fig. 4 , highly purified B cells from two children with primary IgA deficiency (ZAR and JUS) produced IgA in response to IL-10. As observed earlier with IgA-D PBMNC, IL-10 enhanced the production of IgG and IgM by purified B cells of these IgA-D patients (Fig. 4) However, as shown in Fig. 5 , PBMNC from IgA-D patients activated with SAC, PHA and IL-2 (21) produced significant levels of IL-10, ranging from 0.5-1.8 ng/ml (mean+SD = 1.1+0.5). Note, this amount of IL-10 is significantly lower (P = 0.0019, Mann and Withney U test) than that obtained with normal control PBMNC (mean±SD = 2.8+0.5). At the end of cultures, levels of IL-10 produced by PBMNC in response to anti-CD40 mAb/SAC activation were in the order of 500 pg/ml with no significant differences noted between IgA-D patients and controls (not shown).
Next, we explored whether the reduced production of IL-10 by cells from IgA-D patients could be due to increased Because of limited sample size, most of our study was performed with whole blood mononuclear cells. However, we were able to purify B lymphocytes from two primary IgA-D patients (ZAR and JUS) which IgA secretion by PBMNC reached nearly normal amounts in response to IL-10. Highly purified blood B cells (95% pure) from those primary IgA-D patients were also induced to secrete levels of IgA comparable to those of normal donors. It is unlikely that the remaining 5% contaminant non-B cells may play an indirect role in the effect of IL-10 on IgA synthesis. Also, we have reported previously that sIgD+ naive B cells (> 98% pure) isolated from tonsils secreted low but reproducible levels of IgA in response to IL-10 when activated through CD40 (12) . However, it is not known whether CD40 triggering and/or addition of IL-10 enhances the production of ...\sv, [19] zg/ml [IL-10] ng/ml and that TGFB strongly enhances this effect (12) . Furthermore, treatment of mice with anti-IL-10 antibodies results in a strong decrease of circulating IgM and IgA (28). It was thus tempting to hypothesize that IgA-D patients may suffer either from a deficit of IL-10 production or from the presence of an IL-10 antagonist. However, mononuclear cells from IgA-D patients were found to produce IL-10 after optimal activation with SAC and PHA, although the levels were slightly lower than those of normal controls. Also, the production of IFNy which has been shown to antagonize the production of IL-10 (23 ) was comparable with that obtained with normal donor cells. Levels of L-10 synthesis induced in SAC and anti-CD40 mAb cultures were low but comparable with normal individuals and IgA-D patients. The fact that a number of cytokines were present in supernatants of activated cells did not allow us to determine whether the L-10 of IgA-D patients was biologically active. As neutralizing circulating antibodies against ILla (29) , IL-2 (30), IL-6 (31) , and IFNy (32) have been described, the presence of anti-I10 antibodies was investigated. While anti-IL-10 antibodies could be found in some rare individuals (C. Caux-Menetrier and F. Briere, manuscript in preparation), they could not be detected in the serum of the 13 IgA-D patients tested. Our future studies will aim at determining whether primary IgA-D patients display functional IL-10 or whether they have an IL-10 antagonist such as soluble IL-10 receptor. This would appear particularly relevant for IgA deficiency associated with IgGI and IgG3 deficiencies (33) since we recently found that IL-10 induces naive sIgD + B cells to specifically produce these IgG subclasses (34) . Alternatively, these patients may have a blockade in IL-10 production at the physiological sites of B cell differentiation into plasma cells, namely the bone marrow and/or the mucosal lamma propria.
The present study provides a framework for an understanding of the defect underlying the heterogeneous nature of IgA deficiency. In particular, unraveling the molecular mechanisms controlling IL-lO-induced differentiation of normal B cells may eventually permit us to understand the basis for the differentiation blockade of IgA-committed B cells in IgA-D patients. In this context, the possibility of a defective CD40 ligand was ruled out, as activated T cells of IgA-D patients express the CD40 ligand which bound a CD40-Fc fusion protein (data not shown). This was indeed expected because patients with altered CD40 ligand are unable to mount isotype switch (35) (36) (37) (38) .
In conclusion, the present study indicates that the combination of anti-CD40 mAb, SAC and IL-10 induces B cells from IgA-D patients to produce considerable amounts of IgA. Thus, IL-10 appears to be critical in releasing the differentiation blockade of IgA-committed B cells.
